“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

17 June 2019
Pharma

Visiongain has launched a new pharma report Global Ophthalmic Drugs Market Forecast 2019-2029: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs.

The market for ophthalmic drugs is relatively fragmented with a large number of drugs competing for market shares. We note that there are many drugs within the various sectors of the market that have lost exclusivity in the major markets and have therefore been subjected to generic drug competition. Despite generic penetration, the global market for ophthalmic drugs is a growing one with a hive of activities and multiple products in various stages of development.

The lead analyst of the report commented "The market for ophthalmic drugs is a growing one. Although it is currently dominated by a handful of companies, the market still provides opportunities for companies looking to introduce innovative solutions to meet the chronic needs within the market.

Blockbuster drugs are becoming increasingly few within the market as drugs become more targeted. We note that future growth within ophthalmic drugs will likely be driven by innovation from smaller players, possibly in partnership with one of the major companies in the market. The increased demand for drugs and the efforts going into R&D will benefit these smaller players and help to stimulate their growth over the forecast period. With many targeting eye diseases and conditions where significant unmet treatment needs exist, rapid uptake of these products can be expected."

Leading companies featured in the report include Allergan (Actavis), Bayer, Novartis, Pfizer, Regeneron, Roche, Santen, Senju, Valeant and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Rare Diseases Market Report 2021-2031

As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.

02 March 2021

Read

Visiongain Publishes Respiratory Inhalers Market Report 2021-2031

Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.

26 February 2021

Read

Visiongain Publishes Bile Duct Cancer Drugs Market Report to 2031

The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.

22 February 2021

Read

Visiongain Publishes Big Data Analytics in Healthcare Market Report to 2031

The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.

22 February 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever